International audienceBackground: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies.Methods: Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment eff...
Background: In the absence of evidence from randomised controlled trials, observational data can be ...
© 2021 Elsevier B.V.Background: Natalizumab and fingolimod were the first preparations recommended f...
BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthro...
International audienceBackground: Natalizumab and fingolimod are used as high-efficacy treatments in...
Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple scle...
Background: In the absence of evidence from randomised controlled trials, observational data can be ...
Background: In the absence of evidence from randomised controlled trials, observational data can be ...
© 2021 Elsevier B.V.Background: Natalizumab and fingolimod were the first preparations recommended f...
BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthro...
International audienceBackground: Natalizumab and fingolimod are used as high-efficacy treatments in...
Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple scle...
Background: In the absence of evidence from randomised controlled trials, observational data can be ...
Background: In the absence of evidence from randomised controlled trials, observational data can be ...
© 2021 Elsevier B.V.Background: Natalizumab and fingolimod were the first preparations recommended f...
BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthro...